Greater Effectiveness and Enhanced Safety Profiles of Biosimilars Compared to Their Reference Biologics Increasing Their Adoption Worldwid ...

The global Central Lab Services/Clinical Trial Lab Services Market, valued at US$5.64 billion in 2024, is forecasted to grow at a robust CAGR ...

The sector is already on a growth trajectory, with exports reaching $27.9 billion in the fiscal year 2023-24 (April ...

Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...

Contract Development and Manufacturing Organizations (CDMOs) enhance drug discovery by providing essential services that ...

Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for HLX22, the company's innovative anti-HER2 monoclonal ...

The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

A key trend seen in 2024 and recent years is the simplification of basket sizes, as countries look to streamline and simplify.